LINCOLNSHIRE, Ill.–Nexus Pharmaceuticals announced today that it has received U.S. Food and Drug Administration (FDA) approval for Potassium Chloride in Water for Injection in 10mEq/100mL, 10mEq/50mL, 20mEq/100mL, 40mEq/100mL and 20mEq/50mL Single-Dose IV bags....
LINCOLNSHIRE, Ill.–Nexus Pharmaceuticals, Inc. is pleased to announce that it has received authorization to occupy its new pharmaceutical manufacturing facility from the Village of Pleasant Prairie, Wisconsin. Nexus Pharmaceuticals, which specializes in...
PLEASANT PRAIRIE, WI.–Nexus Pharmaceuticals Chief Strategy Officer, Omair Ahmed, joined nine BioForward member organizations in a discussion regarding the Wisconsin biohealth industry’s response to the COVID-19 pandemic. “We pride ourselves in...
PLEASANT PRAIRIE, WI.–Nexus Pharmaceuticals Inc. plans to complete its nearly $100 million Pleasant Prairie sterile injectables plant in April 2021 and a company executive said it will help address the United States’ reliance on foreign pharmaceutical suppliers...
LINCOLNSHIRE, Ill.–Nexus Pharmaceuticals is pleased to announce their continuous certification as a Minority Business Enterprise (MBE) and a Women’s Business Enterprise (WBE). The diversity-based certifications, appointed by the National Minority Supplier...
